{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:31:27Z","timestamp":1790872287591,"version":"4.1.0"},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,5,5]],"date-time":"2004-05-05T00:00:00Z","timestamp":1083715200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the efficacy and survival benefit of low\u2010dose fluconazole (400\u2003mg weekly) for primary prophylaxis for cryptococcal meningitis in patients with advanced HIV infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective multicentre, randomized, double\u2010blind, placebo\u2010controlled study was carried out in HIV\u2010infected patients with CD4 counts &lt;100\u2003cells\/\u03bcL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 90 patients enrolled, 44 received fluconazole and 46 received placebo. The baseline characteristics were similar in the two groups. On an intent\u2010to\u2010treat basis, 10 cases of cryptococcal meningitis developed, three (6.8%) in the fluconazole group and seven (15.2%) in the placebo group. Patients in the placebo group were more likely to develop cryptococcal meningitis than those in the fluconazole group [hazard ratio=2.23; 95% confidence interval (CI): 0.58\u20138.63; <jats:italic>P<\/jats:italic>=0.245]. The survival benefit of fluconazole was greater than that of the placebo. The number of deaths per 10 000 person\u2010days was 2.7 for the fluconazole group (2\/7342) and 11.7 for the placebo group (9\/7713) (rate difference=9; 95% CI: 0.4\u201317.5; <jats:italic>P<\/jats:italic>=0.046). Based on survival analysis, patients in the placebo group were 4.3 times more likely to die than those in the fluconazole group (95% CI: 0.9\u201319.8; <jats:italic>P<\/jats:italic>=0.065).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fluconazole 400\u2003mg once weekly for primary prophylaxis for cryptococcal meningitis in Thailand should be considered in HIV\u2010infected patients, as our study suggested a survival benefit. However, a larger study should be conducted to confirm our findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2004.00201.x","type":"journal-article","created":{"date-parts":[[2004,5,5]],"date-time":"2004-05-05T11:50:54Z","timestamp":1083757854000},"page":"140-143","source":"Crossref","is-referenced-by-count":54,"title":["A multicentre, randomized, double\u2010blind, placebo\u2010controlled trial of primary cryptococcal meningitis prophylaxis in HIV\u2010infected patients with severe immune deficiency"],"prefix":"10.1111","volume":"5","author":[{"given":"P","family":"Chetchotisakd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Thinkhamrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Mootsikapun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Boonyaprawit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,5,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"955","article-title":"Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994\u201398","volume":"32","author":"Chariyalertsak S","year":"2001","journal-title":"regional variation and temporal trends"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.5.837"},{"key":"e_1_2_6_4_2","first-page":"1","article-title":"Guidelines for the Prevention of Opportunistic Infections Among HIV\u2010Infected Person 2002","volume":"51","author":"Kaplan JE","year":"2002","journal-title":"Recommendations of the US Public Health Service and the Infectious Diseases Society of America"},{"key":"e_1_2_6_5_2","first-page":"373","article-title":"The cost\u2010effectiveness of fluconazole prophylaxis against primary systemic fungal infection in AIDS","volume":"17","author":"Scharfstein J","year":"1997","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/515018"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/338154"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503163321102"},{"key":"e_1_2_6_9_2","first-page":"1049","article-title":"Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection","volume":"28","author":"McKinsey DS","year":"1999","journal-title":"randomized, placebo-controlled, double-blind study"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2004.00201.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2004.00201.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:54:26Z","timestamp":1696913666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2004.00201.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1111\/j.1468-1293.2004.00201.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2004.00201.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}